PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

Top Tweets from J.P. Morgan 2017

Research Responses to Patient Privacy Concerns

War Games: Win Your Brand with Action

Executive Profile

Biopharma Change Agent: Belén Garijo

Belén Garijo, CEO of Merck KGaA, Darmstadt, shares her approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.
... /Read more/

Value-Based Engagement Models: Making Collaborations between Pharma and Health Systems Work
Live Webinar: Tuesday, February 7 at 11:00am EST

Opinion

Path of Uncertainty: Pharm Exec's 2017 Industry Forecast

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.
... /Read more/

Biologics Manufacturing – Is Your Company Ready?
Live Webinar: Thursday, February 16 at 11:00am EST

Regulatory Affairs

Obstacles to Europe's HTA ambitions

The long-cherished dream of finding a European approach to assessing the value of new medicines seems to recede further with every step taken to pursue it, writes Reflector.
... /Read more/

From Big Data to Measurable Outcomes: Success with Value-Based Contracts
On Demand

Learn more

Regulatory Affairs

Connecting the Dots for an Enraged Media

Rethinking views on limited-efficacy drug approvals may be in order, says Casey McDonald.
... /Read more/

Calendar

/ PCC 2017 - CBI's 14th Annual Pharmaceutical Compliance Congress 1/27-1/28 /

/ The American Biomanufacturing Summit 5/23-5/24 /

Regulatory Affairs

Right Care for Health: Implications for Pharma

The Lancet's series of papers on moving from universal health care to "right care" for health offers a global and comprehensive perspective, writes Leela Barham. But what does "right care" mean for the industry?
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com